Kemp Stephan, Valianpour Fredoen, Denis Simone, Ofman Rob, Sanders Robert-Jan, Mooyer Petra, Barth Peter G, Wanders Ronald J A
Laboratory Genetic Metabolic Diseases, Department of Pediatrics/Emma Children's Hospital and Clinical Chemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.
Mol Genet Metab. 2005 Feb;84(2):144-51. doi: 10.1016/j.ymgme.2004.09.015.
X-linked adrenoleukodystrophy (X-ALD) is a progressive neurodegenerative disorder characterized by the accumulation of saturated and mono-unsaturated very long-chain fatty acids (VLCFA) and reduced peroxisomal VLCFA beta-oxidation activity. In this study, we investigated the role of VLCFA biosynthesis in X-ALD fibroblasts. Our data demonstrate that elongation of both saturated and mono-unsaturated VLCFAs is enhanced in fibroblasts from patients with peroxisomal beta-oxidation defects including X-ALD, and peroxisome biogenesis disorders. These data indicate that enhanced VLCFA elongation is a general phenomenon associated with an impairment in peroxisomal beta-oxidation, and not specific for X-ALD alone. Analysis of plasma samples from patients with X-ALD and different peroxisomal beta-oxidation deficiencies revealed increased concentrations of VLCFAs up to 32 carbons. We infer that enhanced elongation does not result from impaired peroxisomal beta-oxidation alone, but is due to the additional effect of unchecked chain elongation. We demonstrate that elongated VLCFAs are incorporated into complex lipids. The role of chain elongation was also studied retrospectively in samples from patients with X-ALD previously treated with "Lorenzo's oil." We found that the decrease in plasma C26:0 previously found is offset by the increase of mono-unsaturated VLCFAs, not measured previously during the trial. We conclude that evaluation of treatment protocols for disorders of peroxisomal beta-oxidation making use of plasma samples should include the measurement of saturated and unsaturated VLCFAs of chain lengths above 26 carbon atoms. We also conclude that chain elongation offers an interesting target to be studied as a possible mode of treatment for X-ALD and other peroxisomal beta-oxidation disorders.
X连锁肾上腺脑白质营养不良(X-ALD)是一种进行性神经退行性疾病,其特征是饱和及单不饱和极长链脂肪酸(VLCFA)积累,过氧化物酶体VLCFAβ氧化活性降低。在本研究中,我们调查了VLCFA生物合成在X-ALD成纤维细胞中的作用。我们的数据表明,在包括X-ALD在内的过氧化物酶体β氧化缺陷患者以及过氧化物酶体生物发生障碍患者的成纤维细胞中,饱和及单不饱和VLCFAs的延长均增强。这些数据表明,VLCFA延长增强是与过氧化物酶体β氧化受损相关的普遍现象,并非X-ALD所特有。对X-ALD患者及不同过氧化物酶体β氧化缺陷患者的血浆样本分析显示,碳链长度达32的VLCFAs浓度升高。我们推断,延长增强并非仅由过氧化物酶体β氧化受损导致,而是由于未受抑制的链延长的额外作用。我们证明,延长的VLCFAs被整合到复合脂质中。我们还对先前接受“洛伦佐油”治疗的X-ALD患者样本进行了回顾性研究,以探讨链延长的作用。我们发现,先前发现的血浆C26:0降低被单不饱和VLCFAs的增加所抵消,而在试验期间之前未对其进行测量。我们得出结论,利用血浆样本评估过氧化物酶体β氧化障碍的治疗方案应包括测量碳链长度超过26个碳原子的饱和及不饱和VLCFAs。我们还得出结论,链延长作为X-ALD和其他过氧化物酶体β氧化障碍的一种可能治疗方式,是一个值得研究的有趣靶点。